Replies to post #176907 on Biotech Values

[DewDiligence]

ABT will do fine as a long-term hold, IMO. It has a moderate valuation and all of its main businesses (branded generic drugs, diagnostics, vascular and ophthalmic devices, nutritional products) are strong beneficiaries of The Global Demographic Tailwind. ABT is one company where investors don’t have to be unduly concerned about quarterly results.

[DewDiligence]

ABT—As an addendum to #msg-100711365, the next post shows ABT’s 1Q14 business segments and the degree to which they rely on ex-US sales.